These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10930673)

  • 1. Immunity to diphtheria among children in Northern Norway and North-Western Russia.
    Skogen V; Jenum PA; Danilov E; Korolev VN; Halvorsen DS; Sjursen H
    Vaccine; 2000 Sep; 19(2-3):197-203. PubMed ID: 10930673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunity to diphtheria in northern Norway and northwestern Russia.
    Jenum PA; Skogen V; Danilova E; Eskild A; Sjursen H
    Eur J Clin Microbiol Infect Dis; 1995 Sep; 14(9):794-8. PubMed ID: 8536728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contraindications to vaccination in the Russian Federation.
    Tatochenko V; Mitjushin IL
    J Infect Dis; 2000 Feb; 181 Suppl 1():S228-31. PubMed ID: 10657219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The efficacy of immunizing children who are forced migrants against diphtheria and tetanus based on the results of serological studies].
    Nikitiuk NF
    Zh Mikrobiol Epidemiol Immunobiol; 2000; (3):75-6. PubMed ID: 10925883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: implications for the timing of a booster dose.
    Trollfors B; Knutsson N; Taranger J; Mark A; Bergfors E; Sundh V; Lagergård T
    Eur J Pediatr; 2006 Jan; 165(1):14-8. PubMed ID: 16249929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age.
    Dagan R; Igbaria K; Piglansky L; Van Brusteghem F; Melot V; Kaufhold A
    Vaccine; 1999 Jun; 17(20-21):2620-7. PubMed ID: 10418911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium.
    Vandermeulen C; Theeten H; Rathi N; Kuriyakose S; Han HH; Sokal E; Hoppenbrouwers K; Van Damme P
    Vaccine; 2015 Jun; 33(26):3026-34. PubMed ID: 25613716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of diphtheria among schoolchildren in the Russian Federation in relation to time since last vaccination.
    Vitek CR; Brennan MB; Gotway CA; Bragina VY; Govorukina NV; Kravtsova ON; Rhodes PH; Bisgard KM; Strebel PM
    Lancet; 1999 Jan; 353(9150):355-8. PubMed ID: 9950440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunity of children aged 6-8 against pertussis, tetanus and diphtheria].
    Slusarczyk J; Dulny G; Nowak K; Krszyna J; Wysokińska T; Fordymacka A; Gzyl A; Janaszek W; Gniadek G
    Przegl Epidemiol; 2002; 56(1):39-48. PubMed ID: 12150066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations.
    Launay O; Toneatti C; Bernède C; Njamkepo E; Petitprez K; Leblond A; Larnaudie S; Goujon C; Ungeheuer MN; Ajana F; Raccurt C; Beytout J; Chidiac C; Bouhour D; Guillemot D; Guiso N
    Hum Vaccin; 2009 May; 5(5):341-6. PubMed ID: 19221513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
    Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
    Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprotection against diphtheria and tetanus among Russian and Norwegian teenagers.
    Danilova E; Shiryayev A; Kristoffersen EK; Sjursen H
    APMIS; 2006 Jun; 114(6):453-7. PubMed ID: 16856968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Collective immunity to diphtheria in the children and adolescents of Vladivostok during a mass immunization against this infection].
    Besednova NN; Kudrina NV; Kuznetsova TA; Zaporozhets TS; Lunika IG; Belogolovkina NA; Ivanova NIu; Voronok VM
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (5):82-4. PubMed ID: 9432857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization coverage and immunity to diphtheria and tetanus among children in Hyderabad, India.
    Murhekar MV; Bitragunta S; Hutin Y; Ckakravarty A; Sharma HJ; Gupte MD
    J Infect; 2009 Mar; 58(3):191-6. PubMed ID: 19195713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross-sectional study of Bordetella pertussis seroprevalence and estimated duration of vaccine protection against pertussis in St. Petersburg, Russia.
    Kurova N; Timofeeva EV; Guiso N; Macina D
    Vaccine; 2018 Dec; 36(52):7936-7942. PubMed ID: 30448334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
    John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
    Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
    Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.